3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
6
Sarcoma
3
Plasma cell
2
Other hematologic neoplasm
2
Lymphoid
2
Dermatologic
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
111
Pheochromocytoma
33
Carcinoma, Neuroendocrine
33
Pituitary Neoplasms
28
Thyroid Cancer, Papillary
26
Paraganglioma
26
Adrenocortical Carcinoma
21
Neoplasms
19
Gastro-enteropancreatic neuroendocrine tumor
19
Thyroid Neoplasms
17
Adrenal Gland Neoplasms
16
Multiple Endocrine Neoplasia Type 1
14
Stomach Neoplasms
13
Prostatic Neoplasms
13
Pancreatic Neoplasms
13
Carcinoid Tumor
13
Sarcoma
12
Lung Neoplasms
12
Breast Neoplasms
12
Thyroid Carcinoma, Anaplastic
11
Adenoma, Islet Cell
11
Small Cell Lung Carcinoma
10
Ovarian Neoplasms
10
Neuroblastoma
10
Neoplasm Metastasis
10
Colorectal Neoplasms
10
Carcinoma, Hepatocellular
10
Brain Neoplasms
10
Meningioma
9
Esophageal Neoplasms
9
Interventions
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Erdheim-Chester Disease
×
Endocrine
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled